Currently, there are 741.61M common shares owned by the public and among those 110.45M shares have been available to trade.
The company’s stock has a 5-day price change of -29.32% and -11.96% over the past three months. SMMT shares are trading 2.07% year to date (YTD), with the 12-month market performance up to 662.13% higher. It has a 12-month low price of $2.64 and touched a high of $36.91 over the same period. SMMT has an average intraday trading volume of 3.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.28%, -21.92%, and -10.31% respectively.
Institutional ownership of Summit Therapeutics Inc (NASDAQ: SMMT) shares accounts for 13.23% of the company’s 741.61M shares outstanding.
It has a market capitalization of $13.44B and a beta (3y monthly) value of -0.94. The earnings-per-share (ttm) stands at -$0.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.45% over the week and 9.71% over the month.
Earnings per share for the fiscal year are expected to decrease by -30.93%, and -37.48% over the next financial year. EPS should shrink at an annualized rate of -25.52% over the next five years, compared to -10.52% over the past 5-year period.
Looking at the support for the SMMT, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on March 26, 2025, with the firm’s price target at $23-$35. Evercore ISI was of a view on March 12, 2025 that the stock is Outperform, while Goldman gave the stock Buy rating on February 28, 2025, issuing a price target of $42. Truist on their part issued Buy rating on January 08, 2025.
